Table 1.
ADC stage | Total | ||
---|---|---|---|
0 & 0.5 | ≥1 | ||
N | 69 | 13 | 82 |
Gender (% male) | 84 | 85 | 84 |
Age (years) | 45.5±8.2 | 49.9±9.5 | 48.6±7.5 |
Ethnicity (% Caucasian) | 72 | 62 | 71% |
Education level (% high school or less) | 65 | 77 | 67 |
% IV drug use | 20 | 46 | 24 |
Duration of infection (years) | 12.2±6.1 | 14.3±7.0 | 12.5±6.2 |
CD4 count (log10cells/ml) | 2.54±0.24 | 2.43±0.40 | 2.52±0.27 |
Nadir CD4 (log10cells/ml) | 1.53±0.51 | 1.42±0.40 | 1.51±0.50 |
% undetectable Plasma RNA viral load | 84 | 85 | 84 |
% known on ART at baseline (uninterrupted) | 84 | 62 | 80 |
CPE score | 1.86±1.00 | 1.50±0.71 | 1.81±0.96 |
Note: The two ADC groups did not significantly differ on any demographic or clinical variables.